Inside Information / Other news releases

Press Release Poxel announces the implementation of an equity line with IRIS Capital as part of the execution of the recovery plan

LYON, France, 3 February 2026 - POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, announces the implementation of an equity line with IRIS, known as “SmartATM® “ for a maximum amount of €5 million over five years (terms set out in the Appendix without this amount being guaranteed).

Nicolas Trouche, Chief Executive Officer of Poxel, comments “The establishment of this new equity line with IRIS is an important first step in enabling Poxel to secure the financial foundation necessary to implement its recovery plan. The Company's recovery is now actively underway. “

This financing is part of the restructuring of the bond debt held by IRIS against the Company for a total principal amount of €4,270,000 in the form of bonds redeemable in new or existing shares issued under the issuance agreement entered between Poxel and IRIS, on 22 March 2023.

About Poxel SA

Poxel is a clinical stage biopharmaceutical Company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilised Rpioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel’s first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and 5 sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

For more information, please visit: www.poxel